The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 9, 2011, Pages

  Karner, Charlotta ^a   Cates, Christopher J ^b  

^a BMJ   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; LONG ACTING DRUG; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; SCOPOLAMINE DERIVATIVE;

BINDING AFFINITY; BRONCHODILATATION; BRONCHUS MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BINDING SITE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FORCED EXPIRATORY VOLUME; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; MORTALITY RATE; MOTOR DYSFUNCTION; MUCOCILIARY CLEARANCE; NEGATIVE FEEDBACK; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; XEROSTOMIA; DELAYED RELEASE FORMULATION; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES;

EID: 80055073224     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009039.pub2     Document Type: Review

References (42)

1. Aaron SD, Vandemheen K, Ferguson D, FitzGerald M, Maltais F, Boureau J, et al.The Canadian optimal therapy of COPD trial: Design, organization and patient recruitment. Canadian Respiratory Journal 2004;11(8):581-5.
2. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al.Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. [see comment] [summary for patients in Annals of Internal Medicine 2007 Apr 17;146(8):I12; PMID: 17310044]. Annals of Internal Medicine 2007;146(8):545-55.
3. Kaplan A. Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal 2007;16(4):258-60.
4. Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, et al.Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008;63(11):962-7.
5. Roisman G. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique 2007;63(6):390-1.
6. Golabi P, Topaloglu N, Karakurt S, Celikel T. Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation dyspnea and exercise tolerance in COPD [Abstract]. European Respiratory Journal. 2006; Vol. 28, issue Suppl 50:33s [E304].
7. Hara K, Kurashima K, Tokunaga D, Ueno M, Aoyagi K, Isobe Z, et al.Single blind comparison of tiotropium and salmeterol plus fluticasone propionate of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference, May 18-23, 2007, San Francisco, California, USA. 2007:Poster #A1.
8. Mittmann N, Hernandez P, Mellström C, Brannman L, Welte T. Cost-effectiveness of budesonide/formoterol added to tiotropium in COPD patients in Canada, Australia and Sweden [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22. 2010:[5183].
9. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63(7):592-8.
10. Singh D, Hagan G, Cahn A, Leonard TB, Riley JH, O'Connor BJ. Individual and combined responses to salmeterol/fluticasone propionate combination (SFC) and tiotropium (Tio) shown in a COPD clinical trial [Abstract]. American Thoracic Society International Conference, May 16-21, 2008, Toronto. 2008:A648[#F10].
11. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations. Chest 2010;137(2):318-25.
12. Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. The American Journal of Managed Care 2008;14(7):438-48.
13. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MMK, et al.Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD001104.pub2].
14. Barr RG, Bourbeau J, Camargo Carlos A. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2].
15. Beeh KM, Beier J. The short, the long, and the "ultra-long": Why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Advances in Therapy 2010;27(3):150-9.
16. Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine 2008;102(2):173-88.
17. Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PMA, Jones PW, et al.Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal 2010;35(3):532-9.
18. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. The New England Journal of Medicine 2007;356(8):775-89.
19. Dalal AA, St Charles M, Petersen HV, Roberts MH, Blanchette CM, Manavi-Zieverink K. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 2010;5:179-87.
20. Effing T, Monninkhof EEM, van der Valk PPDLPM, Zielhuis GGA, Walters EH, van der Palen JJ, et al.Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD002990.pub2].
21. Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.com [Accessed 14th December 2009].
22. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.
23. Hutchinson A, Brand C, Irving L, Roberts C, Thompson P, Campbell D. Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Internal Medicine Journal 2010;40(5):364-71.
24. Johnson M. The beta-adrenoceptor. American Journal of Respiratory and Critical Care Medicine 1998;158(5 Pt 3):S146-53.
25. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003793.pub2].
26. Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, et al.Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008;63(11):962-7.
27. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub3].
28. Nannini Luis J, Cates Christopher J, Lasserson Toby J, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006829].
29. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre, 2010. [URL: http://guidance.nice.org.uk/CG101/Guidance/pdf/English].
30. Proskocil BJ, Fryer AD. Beta2-agonist and anticholinergic drugs in the treatment of lung disease. Proceedings of the American Thoracic Society 2005;2(4):305-10; discussion 311-2.
31. The Nordic Cochrane Centre; Cochrane Collaboration. Review Manager (RevMan) Version 5. Copenhagen: The Nordic Cochrane Centre; Cochrane Collaboration, 2008.
32. Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting β-agonists in stable COPD: A systematic review. Chest 2008;133(5):1079-87.
33. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 2009;136(4):1029-38.
34. Jones P. St George's Respiratory Questionnaire for COPD Patients (SGRQ-C). St Georges, University of London 2008.
35. Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2010;5:189-95.
36. Tanaka Y, Horinouchi T, Koike K. New insights into beta-adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation. Clinical and Experimental Pharmacology and Physiology 2005;32(7):503-14.
37. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. The New England Journal of Medicine 2008;359(15):1543-54.
38. van der Meer RM, Wagena E, Ostelo RWJG, Jacobs AJE, van Schayck O. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD002999].
39. Wallukat G. The beta-adrenergic receptors. Herz 2002;27(7):683-90.
40. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD007891].
41. World Health Organization. Chronic Respiratory Diseases. www.who.int.
42. Yang IA, Fong K, Sim EHA, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD002991.pub2].